Eisai Co., Ltd. (“Eisai”) announced today that a future initiative aiming to identify and validate novel drug targets that could potentially lead to the development of new therapeutics and preventive medicines for dementia has been selected by the Japan Agency for Medical Research and Development (AMED) for its Cyclic Innovation for Clinical Empowerment (CiCLE) grant program. This initiative is to be implemented at the Eisai-Keio Innovation Laboratory for Dementia (“EKID”, Location: Keio University’s Shinanomachi Campus), an industry–medico collaboration site established by Eisai and Keio University.

CiCLE by AMED is a grant program to promote the establishment of an infrastructure to respond to medical needs and the creation of an environment for open innovation and venture development based on industry–academia–government collaboration.

An outline of the selected research project is as follows:

- Project title: Industry–medico collaboration laboratory for dementia to create new promising drug targets
- Representative organization: Eisai Co., Ltd.

AMED’s webpage for CiCLE project selections:

http://www.amed.go.jp/koubo/070020170228_kettei01.html (Japanese only)

Through the selection of this R&D project, Eisai seeks to enhance dementia drug target research at EKID, aiming to discover novel drug targets and create next generation treatments.